Will AbbVie back off Humira advertising now that it’s announced it will buy Allergan? Maybe. But for now, the Illinois drugmaker is showing no signs of slowing its long-running robust TV ad push for the world's best-selling drug. AbbVie blasted the nearest competing pharma TV ad by dropping $47.5 million last month, topping the second-closest spender by more than $20 million, according to data from real-time TV ad tracker iSpot.tv. Gilead Sciences came in second in May, spending $26.8 million on ads for HIV treatment and prevention drug Truvada as part of its ongoing TV campaign. Both drugmakers are under the gun facing patent expirations, with Truvada's in 2020 and Humira's in 2023, although biosimilars for Humira are already on the market in Europe. Free Daily Newsletter Like this story? Subscribe to FiercePharma! Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go. SUBSCRIBE NOW Another repeat on the list for May was a second Gilead HIV treatment, the three-drug regimen Biktarvy, at No. 9 with its diversity campaign launched in April. Also on the list again was Celgene’s Otezla, although maybe not for long: Bristol-Myers Squibb announced this week that as part of an agreement with the FTC over its buyout of Celgene, it will sell off the psoriasis blockbuster. Overall, TV ad spending for the pharma top 10 increased to $177 million in May, up from $168 million spent in April and $169 million in March, according to iSpot.tv data. 1. Humira Movement: Stayed same What is it? AbbVie anti-inflammatory drug Total estimated spending: $47.5 million (up from $45.8 million in April) Number of spots: 11 (Six for arthritis, three for ulcerative colitis/Crohn's, two for psoriasis) Biggest-ticket ad: “Citrate Free” (est. $10.9 million) HUMIRA Pen TV Commercial, 'Citrate-Free' 2. Truvada Movement: Not on list last month What is it? Gilead’s HIV and PrEP drug Total estimated spending: $26.8 million Number of spots: One Biggest-ticket ad: “On the Pill” Truvada TV Commercial, 'On the Pill' 3. Xeljanz Movement: Down from No. 2 What is it? Pfizer oral RA and ulcerative colitis med Total estimated spending: $21.1 million (down from $25.8 million in April) Number of spots: Four Biggest-ticket ad: “A Different Direction” (est. $11.1 million) XELJANZ TV Commercial, 'A Different Direction' 4. Latuda Movement: Moved up from No. 5 What is it? Sunovion Pharmaceutical anti-psychotic Total estimated spending: $14.2 million (up from $12.9 million in April) Number of spots: One Biggest-ticket ad: “Lauren’s Story” Latuda TV Commercial, 'Lauren's Story' 5. Eliquis Movement: Moved up from No. 6 What is it? Pfizer and Bristol-Myers Squibb next-gen anticoagulant Total estimated spending: $13.4 million (up from $11.3 million in April) Number of spots: Three Biggest-ticket ad: “Around the Corner” (est. $6.3 million) ELIQUIS TV Commercial, 'Around the Corner' 6. Xarelto Movement: Not on list last month What is it? Johnson & Johnson next-gen anticoagulant Total estimated spending: $12.8 million Number of spots: Three Biggest-ticket ad: “Not Today” (est. $7.5 million) Xarelto TV Commercial, 'Not Today' 7. Emgality Movement: Moved down from No. 4 What is it? Eli Lilly anti-CGRP migraine treatment Total estimated spending: $12.4 million (down from $15.1 million in April)\ Number of spots: One Biggest-ticket ad: “Pirates” Emgality TV Commercial, 'Pirates' 8. Taltz Movement: Stayed same What is it? Eli Lilly next-gen psoriasis treatment Total estimated spending: $10.8 million (down from $10.6 million in April) Number of spots: Four Biggest-ticket ad: “Moving” (est. $3.4 million) Taltz TV Commercial, 'Moving' 9. Biktarvy Movement: Moved down from No. 3 What is it? Gilead Sciences HIV 3-in-1 combo med Total estimated spending: $9.6 million (down from $18.2 million in April) Number of spots: One Biggest-ticket ad: “Keep Being You” Biktarvy TV Commercial, 'Keep Being You' 10. Otezla Movement: Stayed same What is it? Celgene's oral treatment for plaque psoriasis Total estimated spending: $8.3 million (down from $12.4 million in April) Number of spots: Two Biggest-ticket ad: “Summer Days” ($5.6 million) Otezla (Psoriasis) TV Commercial, 'Summer Days'